Chugai Seiyaku Kabushiki Kaisha

Chugai Seikayu Kabushiki Kaisha

Ntt Docomo, Inc.

Hitoshi Yoshino

Takuya Shiraishi

Tsutomu Sato

Satoshi Tsuchiya

Masahiro Nishimoto

Atsushi Matsuo

Hirotaka Kashiwagi

Yoshikazu Nishimura

Nobuyuki Hori

Satoshi Tanida

Masahide Aoki

Yoshiyuki Furuta

Kyoko Oguri

Takuma Kamon

Hiroko Ogawa

Shoshin Yoshida

Takahiro Kawai

Haruhiko Sato

Masateru Ohta

Kazutaka Tachibana

Mitsuaki Nakamura

Hiromitsu Kawata

Ikuhiro Imaoka

Masahiro Nagamuta

Takashi Emura

Atsushi Fujiwara

Shinji Takeda

Toru Otsu

Etsuro Onuma

Kenji Taniguchi

Akie Honma

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

An imidazole derivative represented by formula (I): wherein Q is: A is hydrogen, halogen, or a substituted or unsubstituted Calkyl group; E is independently selected from a Calkyl group; Rand Rare independently selected from Calkyls; Xand Xare independently selected from O and S; Y is selected from a substituted or unsubstituted arylene group and a substituted or unsubstituted divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group; Z is &#x2014;CON(&#x2014;Ra)&#x2014;, &#x2014;CO&#x2014;, &#x2014;OOO&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;NH)NRb&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;N&#x2014;CN)NRb&#x2014;, &#x2014;N(&#x2014;Ra)COO&#x2014;, &#x2014;C(&#x2550;NH)&#x2014;, &#x2014;SO&#x2014;, &#x2014;SON(&#x2014;Ra)&#x2014;, &#x2014;SONR&#x2014;, &#x2014;N(&#x2014;Ra)CO&#x2014;, &#x2014;N(&#x2014;Ra)CON(&#x2014;Rb)&#x2014;, &#x2014;N(COR)CO&#x2014;, &#x2014;N(&#x2014;Ra)SO&#x2014;, &#x2014;N(SOR)SO&#x2014;, &#x2014;N(&#x2014;Ra)&#x2014; or &#x2014;N(&#x2014;Ra)SON(&#x2014;Rb)&#x2014;; Ris independently a hydrogen atom, a hydroxyl group, or substituted or unsubstituted group selected from Calkyl group, heterocyclic group, aryl group, Ccycloalkyl group and Ccycloalkenyl group; or salt or prodrug thereof.

Imidazolidine derivative and use thereof

The present invention provides a compound represented by formula (I):  A is cyano or the like; B is hydrogen, halogen, or the like; Xand Xare each independently selected from O and S; E is a Calkyl group; and R, R, Rand Rare each independently selected from a hydrogen atom and a C-Calkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.

Imidazolidine derivatives

The present invention provides a compound represented by formula (I): [Formula 1] wherein n is an integer selected from 1 to 20, and Rand R, which may be the same or different, each represent a hydrogen atom, or a linear or branched C-Calkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.

Growing community of inventors

Gotenba, Japan

Hitoshi Yoshino